← 返回

STING 与 TOX 协同抑制 HO-1 表达,触发肿瘤浸润 CD8+ T 细胞铁死亡及免疫治疗耐药

英文原题:STING synergizes with TOX suppressing HO-1 expression to trigger ferroptosis in tumor-infiltrating CD8+ T cell and immunotherapy resistance.

查看英文原题

STING synergizes with TOX suppressing HO-1 expression to trigger ferroptosis in tumor-infiltrating CD8+ T cell and immunotherapy resistance.

PubMed 2026/02/09(内容时间) Nat Commun Q1 · IF 18.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肿瘤微环境中CD8⁺ T细胞的丰度是免疫治疗疗效的关键决定因素。本研究表明,缺乏STING或TOX的CD8⁺ T细胞表现出显著增强的抗肿瘤活性,伴有肿瘤浸润增强以及IFN-γ和颗粒酶B产生增加。这些STING或TOX缺陷细胞呈现干细胞样转录状态,并通过抑制脂质过氧化通路同时促进线粒体生物发生来抵抗铁死亡。在机制上,STING和TOX形成正调控环路,抑制HO-1表达,导致肿瘤浸润CD8⁺ T细胞中铁蓄积、线粒体氧化应激和铁死亡。我们进一步鉴定乳酸为微环境触发STING-TOX-HO-1介导的CD8⁺ T细胞铁死亡的因子。在小鼠肿瘤模型中,工程化的STING/TOX缺陷CD8⁺ T细胞与免疫检查点阻断、化疗或STING激动剂协同增强肿瘤控制。这些发现揭示了调控肿瘤中CD8⁺ T细胞铁死亡的核心通路,并提出了克服免疫治疗耐药的治疗策略。

展开英文摘要原文

CD8 + T cell abundance within the tumor microenvironment is a critical determinant of immunotherapy efficacy.

Here we show that CD8⁺ T cells lacking STING or TOX display markedly improved antitumor activity, with enhanced tumor infiltration and elevated IFN-γ and granzyme B production. These STING or TOX deficient cells exhibit a stem-like transcriptional state and resist ferroptosis by suppressing lipid peroxidation pathways while promoting mitochondrial biogenesis.

Mechanistically, STING and TOX form a positive regulatory loop that represses HO-1 expression, leading to iron accumulation, mitochondrial oxidative stress, and ferroptosis in tumor-infiltrating CD8⁺ T cells.

We further identify lactate as a microenvironmental trigger of STING-TOX-HO-1-mediated CD8 + T-cell ferroptosis. In mouse tumor models, engineered STING/TOX-deficient CD8⁺ T cells synergize with immune checkpoint blockade, chemotherapy, or STING agonist to enhance tumor control.

These findings reveal a central pathway governing CD8⁺ T-cell ferroptosis in tumors and suggest therapeutic strategies to overcome immunotherapy resistance.

论文信息

作者
Zhu Q、Zhang JB、Nie CP、Liu XF、Zhan LP、Li M、Zeng XL、He J
第一作者单位
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.China
通讯作者单位
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. lijiang2@mail.sysu.edu.cn.China
期刊
Nature communications2026 Feb 9
原文标识
PubMed 41663385 · DOI 10.1038/s41467-026-69350-y